GlassScriptPhysician profile
Amanda Sandles
NPI 1437772696
$4,831.60
in general payments reported to CMS, 2019-2025
29 companies · $2,240 in 2025
The $2,240 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $230 · 2023: $1,433 · 2024: $929 · 2025: $2,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,463 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,463.28 |
| Education | $138.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $973.25 | 2023-2025 | Accolade Sr, Watchman Flx, Avvigo Guidance System |
| Medtronic, INC. | $655.90 | 2022-2025 | Cobalt Dr Mri Surescan, Linq II, Micra |
| Inari Medical, INC. | $643.41 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $396.19 | 2025 | |
| Kestra Medical Technology Services, INC. | $335.61 | 2025 | Assure Wcd |
| Amgen INC. | $279.81 | 2022-2025 | Repatha, Repatha |
| Novo Nordisk INC | $226.38 | 2025 | Wegovy |
| Abbott Laboratories | $186.49 | 2024-2025 | Ensite, Cardiomems, Jot Dx |
| Merck Sharp & Dohme LLC | $163.80 | 2023-2025 | Verquvo, Capvaxive |
| Penumbra, INC. | $162.33 | 2025 | Indigo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.78 | 2023 | Jardiance |
| Pfizer INC. | $78.79 | 2024-2025 | |
| Madrigal Pharmaceuticals | $68.81 | 2025 | Rezdiffra |
| Terumo Medical Corporation | $65.87 | 2023-2024 | Angio-Seal, Tr Band, Glidesheath Slender |
| Kiniksa Pharmaceuticals International, Plc | $64.44 | 2024 | Arcalyst |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $50.00 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Sanofi-Aventis U.S. LLC | $49.06 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $48.84 | 2023-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $36.73 | 2024 | Xarelto |
| United Therapeutics Corporation | $33.74 | 2025 | Tyvaso |
| Lantheus Medical Imaging, INC. | $27.63 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $26.39 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $25.25 | 2025 | Uptravi, Opsumit |
| Alnylam Pharmaceuticals INC. | $23.71 | 2023 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $23.32 | 2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $22.92 | 2025 | |
| Teleflex LLC | $20.49 | 2025 | Turnpike |
| Ardelyx, INC. | $14.42 | 2023 | Ibsrela |
| Philips North America LLC | $13.24 | 2024 | (Ck4) Mcot |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Sandles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.